Cargando…
Impact of the TNM staging system for thymoma
BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801005/ https://www.ncbi.nlm.nih.gov/pubmed/35118337 http://dx.doi.org/10.21037/med-21-24 |
_version_ | 1784642349958168576 |
---|---|
author | Smith, Alex Cavalli, Camilla Harling, Leanne Harrison-Phipps, Karen Routledge, Tom Pilling, John King, Juliet Bille, Andrea Nonaka, Daisuke |
author_facet | Smith, Alex Cavalli, Camilla Harling, Leanne Harrison-Phipps, Karen Routledge, Tom Pilling, John King, Juliet Bille, Andrea Nonaka, Daisuke |
author_sort | Smith, Alex |
collection | PubMed |
description | BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging system in 2014. This study aims to evaluate its impact on stage distribution, clinical implementation, and prognosis for thymomas. METHODS: We performed a single institution, retrospective analysis of 245 consecutive patients who underwent surgical resection for thymoma. 9 patients with thymic carcinoma were excluded. No patients were lost to follow up. Kaplan-Meier survival analysis was used to calculate overall survival. RESULTS: Median age was 62 years; 129 patients (53%) were female. The median overall survival was 158 months (range, 108–208 months), and disease-free survival 194 months (range, 170–218 months). At the end of follow up 63 patients were dead. Early Masaoka-Koga stages I (n=74) and II (n=129) shifted to the IASLC/ITMIG stage I (n=203). 8 patients were down staged from Masaoka-Koga stage III to IASLC/ITMIG stage II because of pericardial involvement. Advanced stages III (Masaoka-Koga: n=30; IASLC/ITMIG: n=22) and IV (Masaoka-Koga: n=12; IASLC/ITMIG: n=12) remained similar and were associated with more aggressive WHO thymoma histotypes (B2/B3). Masaoka-Koga (P=0.004), IASLC/ITMIG staging (P<0.0001) and complete surgical resection (P<0.0001) were statistically associated with survival. At multivariate analysis only R status was an independent prognostic factor for survival. CONCLUSIONS: The proportion of patients with stage I disease increased significantly when IASLC/ITMIG system used, whilst the proportion with stages III and IV were similar in both systems. Completeness of resection, Masaoka-Koga and the IASLC/ITMIG staging system are strong predictors of survival. The TNM staging system is useful in disease management and a strong predictor of overall survival. |
format | Online Article Text |
id | pubmed-8801005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-88010052022-02-02 Impact of the TNM staging system for thymoma Smith, Alex Cavalli, Camilla Harling, Leanne Harrison-Phipps, Karen Routledge, Tom Pilling, John King, Juliet Bille, Andrea Nonaka, Daisuke Mediastinum Original Article BACKGROUND: Masaoka-Koga staging system remains the most frequently applied clinical staging system for thymic malignancy. However, the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposed a tumor-node-metastasis (TNM) staging system in 2014. This study aims to evaluate its impact on stage distribution, clinical implementation, and prognosis for thymomas. METHODS: We performed a single institution, retrospective analysis of 245 consecutive patients who underwent surgical resection for thymoma. 9 patients with thymic carcinoma were excluded. No patients were lost to follow up. Kaplan-Meier survival analysis was used to calculate overall survival. RESULTS: Median age was 62 years; 129 patients (53%) were female. The median overall survival was 158 months (range, 108–208 months), and disease-free survival 194 months (range, 170–218 months). At the end of follow up 63 patients were dead. Early Masaoka-Koga stages I (n=74) and II (n=129) shifted to the IASLC/ITMIG stage I (n=203). 8 patients were down staged from Masaoka-Koga stage III to IASLC/ITMIG stage II because of pericardial involvement. Advanced stages III (Masaoka-Koga: n=30; IASLC/ITMIG: n=22) and IV (Masaoka-Koga: n=12; IASLC/ITMIG: n=12) remained similar and were associated with more aggressive WHO thymoma histotypes (B2/B3). Masaoka-Koga (P=0.004), IASLC/ITMIG staging (P<0.0001) and complete surgical resection (P<0.0001) were statistically associated with survival. At multivariate analysis only R status was an independent prognostic factor for survival. CONCLUSIONS: The proportion of patients with stage I disease increased significantly when IASLC/ITMIG system used, whilst the proportion with stages III and IV were similar in both systems. Completeness of resection, Masaoka-Koga and the IASLC/ITMIG staging system are strong predictors of survival. The TNM staging system is useful in disease management and a strong predictor of overall survival. AME Publishing Company 2021-12-25 /pmc/articles/PMC8801005/ /pubmed/35118337 http://dx.doi.org/10.21037/med-21-24 Text en 2021 Mediastinum. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Smith, Alex Cavalli, Camilla Harling, Leanne Harrison-Phipps, Karen Routledge, Tom Pilling, John King, Juliet Bille, Andrea Nonaka, Daisuke Impact of the TNM staging system for thymoma |
title | Impact of the TNM staging system for thymoma |
title_full | Impact of the TNM staging system for thymoma |
title_fullStr | Impact of the TNM staging system for thymoma |
title_full_unstemmed | Impact of the TNM staging system for thymoma |
title_short | Impact of the TNM staging system for thymoma |
title_sort | impact of the tnm staging system for thymoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801005/ https://www.ncbi.nlm.nih.gov/pubmed/35118337 http://dx.doi.org/10.21037/med-21-24 |
work_keys_str_mv | AT smithalex impactofthetnmstagingsystemforthymoma AT cavallicamilla impactofthetnmstagingsystemforthymoma AT harlingleanne impactofthetnmstagingsystemforthymoma AT harrisonphippskaren impactofthetnmstagingsystemforthymoma AT routledgetom impactofthetnmstagingsystemforthymoma AT pillingjohn impactofthetnmstagingsystemforthymoma AT kingjuliet impactofthetnmstagingsystemforthymoma AT billeandrea impactofthetnmstagingsystemforthymoma AT nonakadaisuke impactofthetnmstagingsystemforthymoma |